Vancouver, British Columbia – March 14th , 2019 – Biocure Technology Inc. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) is pleased to announce that effective of today’s date, Mr. Danny Joh has been appointed as a director of Biocure Technology Inc.
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that effective of today's date, Mr. Danny Joh has been appointed as a director of Biocure Technology Inc.
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2019) -Biocure Technology Corp. (CSE:CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 96,404 shares at $11.45 CAD per share for gross proceeds of $1,103,749. After the issuance of new BPK shares, CURE holds now 97.32% interest in BPK.
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has entered into a Memorandum of Understanding with the Agency of Development of the Pharmaceutical Industry under the Ministry of Health, The Republic of Uzbekistan (herein after called "MHU") and Gold-Dream LLC (herein after called "GDL") on Feb 15th, 2019 in Korea. The delegates from MHU visited the city of Daejeon where BPK is located, for the signing of the MOU and for a tour of the GMP ("Good Manufacturing Practice") standard facilities. The delegates also met with municipality officials from the city of Daejeon.
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF)("CURE" or the "Company") is pleased to announce that it has arranged a non-brokered private placement of 6,976,745 million units at 43 cents per unit for gross proceeds of $3 Million or more, depending on investor interest. Each Unit will entitle the holder to receive one common share of the Company (each a "Common Share") and one Full Warrant ("Warrants") exercisable for 24 Months for CDN$0.86. Each warrant is subject to accelerated expiry provisions, such that if at any time after the expiry of any resale restriction governing the subscribed shares, the corporation's common shares trade on the Canadian Securities Exchange at or above a volume-weighted average trading price of $1.29 per common share for 10 consecutive trading days, the company may give notice to the holders that each warrant will expire 30 days from the date of providing such notice.
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that its OTCQB-listed common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.
VANCOUVER, British Columbia, February 22nd, 2019 -- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea (“BPK”), a wholly owned subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that it has arranged a non- brokered private placement through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK will be issuing up to 100,000 shares at 11,40 CAD per share for gross proceeds of $1.14 Million or more, depending on investor interest. Finder’s fees or commissions may be payable by the Company in connection with this Private Placement.
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has entered into a collaboration agreement with Y Biologics ("YB"), a private R&D company in Korea who is specialized in antibody therapeutics in cancer, autoimmune disease and metabolic disease. The purpose of this agreement is to research the effectiveness of combined treatment of Immune Checkpoint Inhibitor PD-1 (Programmed Cell Death Protein-1) developed by YB and anti-CD19 CAR T-Cell Therapy developed by BPK. BPK and YB believe that the above combined treatment could maximize anticancer effects and eventually develop a next generation anticancer treatment for solid tumors.
Vancouver, British Columbia – November 19, 2018 – Biocure Technology Inc. (CSE: CURE, OTCQB; BICTF) (the “Company” or “Biocure”) is pleased to provide a shareholders’ update on its operations.
The trial was conducted under Korea FDA guidelines and represents the first anti-CD19 CAR-T cell immunotherapy in Korean history
Company plans clinical trials already in 2019 with possible commercialization in 2020
Dr. Sang Mok Lee, CEO commented, "This is a major milestone for cancer treatments. Our results are extremely encouraging, and we plan to responsibly advance towards commercialization of this potentially life-saving treatment."
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2018) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") announces today the successful results of the Pre-Clinical Trial of safety and toxicity of CAR-T cells based treatment for Acute Lymphocytic Leukemia.
Vancouver, British Columbia – September 4th, 2018 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure”) is pleased to announce that effective of today’s date, Mr. Hans Frykman has been appointed as a director of Biocure Technology Inc.
Vancouver, BC - July 18, 2019 - BioCure Technology Inc. (CSE:CURE, OTCQB;BICTF) (“BioCure” or the “Company”) is pleased to announce that its wholly owned subsidiary BiocurePharm Corporation (“BP Korea”), has implemented the preclinical trial of Interferon Beta 1b since late 2017 and is pleased to update shareholders on their progress. BP Korea announces that it has completed most of the toxicity testing and has developed MCB (Master Cell Bank) and WCB (Working Cell Bank). Currently, BP Korea is in the middle of in-Vivo potency test. The Company has already produced 35,000 vials of Interferon Beta 1b for their pre-clinical trial and stability test at the GMP manufacturing facility in Korea. BP Korea expects the pre-clinical trial shall be completed by the end of Q1, 2019 and will advance to clinical trial in 3Q 2019.
Biocure Technology Inc.
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
info@biocuretech.com
+1(604) 609-7146
© Biocure Technology Inc., all rights reserved
